Beauty

Shiseido signs binding deal to sell China's SLC to IDG-led group

Evelina SandbergNovember 19, 20265 min read1 views

At a glance

  • The transaction covers the Aupres maker's Beijing factory and includes IP licensing and transition support.
  • Shiseido has agreed to divest its Chinese subsidiary SLC, which makes and sells Aupres, to an IDG Capital-led investor group, with completion expected between late 2026 and early 2027 pending regulatory approval. The company says the move supports its push for stronger profitability and capital efficiency while retaining transition support for the business.
A conceptual editorial scene showing a cosmetics manufacturing complex and a translucent handover dossier against abstract map-like contours, representing a corporate divestiture and transition.

Shiseido has signed a binding agreement to sell its wholly owned Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor group led by Hong Kong-based private equity firm IDG Capital. SLC makes and sells the Aupres brand in China. The Japanese cosmetics group did not disclose financial terms. The transaction is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China.

The sale is part of Shiseido’s 2030 Medium-Term Strategy, which aims to improve profitability and capital efficiency. Shiseido said it wants to focus management resources on areas where it has the greatest competitive advantage, prioritize brands and pursue higher-growth opportunities. It described China as a strategically important and attractive market, while noting that e-commerce expansion, changing consumer behavior and a more diverse set of competitors are reshaping the competitive landscape.

Ownership and handover arrangements

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. Aupres has been sold since 1994. With the joint venture agreement due to expire in December 2026, the parties agreed not to renew it. Shiseido acquired Beijing Liyuan’s 35% stake on September 1, 2026, giving it full ownership before the sale.

Under the transaction, funds managed by IDG Capital will hold 95% of the equity through two special purpose vehicles. A limited partnership set up mainly by SLC’s new management team will hold the remaining 5%. The deal includes SLC’s Beijing factory and production equipment. Shiseido said independent operation under IDG should support SLC’s sustainable growth and brand value.

To support a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, Shiseido will also provide support on new product development, technical assistance for stable supply of existing products, and continued supply of raw materials and selected products. The company said these arrangements are intended to maintain SLC’s innovation capabilities, product quality and business continuity.

Profit recovery and outlook

The divestment follows Shiseido’s report of a 124.3% increase in core operating profit for the third quarter of 2026, to ¥67.5 billion (US$422.13 million). Shiseido attributed the recovery to restructuring, cost cuts and improved margins rather than strong product demand. Like-for-like sales rose 0.7%.

Shiseido raised its full-year core operating profit forecast to ¥87 billion (US$546 million) from ¥59 billion (US$433 million) after those results. The company frames the SLC sale as a way to shed a business that requires continued investment in product innovation and digital capabilities, allowing the group to concentrate on priority brands and higher-growth opportunities.

Reported by Evelina Sandberg, Skincare Formulation and Sensory Analyst.